12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral anti-CD3 mAb: Phase IIa data

A single-blind, placebo-controlled, Israeli Phase IIa trial in 36 patients showed that once-daily 0.2, 1 and 5 mg doses of NasVax's oral anti-CD3 mAb immunotherapy for 30 days were well tolerated with no treatment-related adverse...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >